GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ZoomMed Inc (TSXV:ZMD.H) » Definitions » Peter Lynch Fair Value

ZoomMed (TSXV:ZMD.H) Peter Lynch Fair Value : N/A (As of May. 19, 2024)


View and export this data going back to 2005. Start your Free Trial

What is ZoomMed Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for ZoomMed's Peter Lynch Fair Value or its related term are showing as below:


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of ZoomMed was 0.50. The lowest was 0.50. And the median was 0.50.


TSXV:ZMD.H's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.36
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


ZoomMed Peter Lynch Fair Value Historical Data

The historical data trend for ZoomMed's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZoomMed Peter Lynch Fair Value Chart

ZoomMed Annual Data
Trend May10 May11 May12 May13 May14 May15 May16 May17 May22 May23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ZoomMed Quarterly Data
Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - - - -

Competitive Comparison of ZoomMed's Peter Lynch Fair Value

For the Health Information Services subindustry, ZoomMed's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZoomMed's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ZoomMed's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where ZoomMed's Price-to-Peter-Lynch-Fair-Value falls into.



ZoomMed Peter Lynch Fair Value Calculation

ZoomMed's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.001
=N/A

ZoomMed's EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


ZoomMed  (TSXV:ZMD.H) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

ZoomMed's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.015/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZoomMed Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of ZoomMed's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ZoomMed (TSXV:ZMD.H) Business Description

Traded in Other Exchanges
N/A
Address
9815 Leduc Boulevard, Suite 503, Brossard, QC, CAN, J4Y 0K8
ZoomMed Inc is a Canada-based company that, together with its subsidiaries, is engaged in the development and marketing of computer applications designed for healthcare professionals. It builds and operates the e-Pic Communication Platform, a clinical interoperable information exchange network between physicians and the various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical corporations, laboratories, specialized clinics private insurers, employers, and others.

ZoomMed (TSXV:ZMD.H) Headlines

No Headlines